Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,085,456 shares of the biotechnology company’s stock after acquiring an additional 117,904 shares during the period. Vanguard Group Inc. owned approximately 9.51% of Sarepta Therapeutics worth $1,104,701,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in SRPT. Daiwa Securities Group Inc. grew its position in Sarepta Therapeutics by 13.8% in the 3rd quarter. Daiwa Securities Group Inc. now owns 3,929 shares of the biotechnology company’s stock valued at $490,000 after buying an additional 475 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Sarepta Therapeutics by 1.3% in the third quarter. Fisher Asset Management LLC now owns 18,155 shares of the biotechnology company’s stock valued at $2,267,000 after acquiring an additional 239 shares in the last quarter. Quantbot Technologies LP purchased a new position in Sarepta Therapeutics during the third quarter worth about $237,000. Blueshift Asset Management LLC purchased a new position in Sarepta Therapeutics during the third quarter worth about $262,000. Finally, Alkeon Capital Management LLC lifted its position in Sarepta Therapeutics by 13.4% in the third quarter. Alkeon Capital Management LLC now owns 633,845 shares of the biotechnology company’s stock valued at $79,161,000 after purchasing an additional 75,000 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $70.41 on Friday. Sarepta Therapeutics, Inc. has a 1 year low of $69.81 and a 1 year high of $173.25. The company’s 50 day simple moving average is $102.66 and its 200 day simple moving average is $116.06. The company has a market capitalization of $6.83 billion, a price-to-earnings ratio of 56.33 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft cut their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research note on Wednesday, March 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $163.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. HC Wainwright reaffirmed a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, March 19th. Royal Bank of Canada reduced their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Finally, Needham & Company LLC restated a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $167.41.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.